

Substituted for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/821,981
Filing Date	April 12, 2004
First Named Inventor	Seth ORLOW
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	ORLOW1A

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/C.B./	AM	WO 02/085349 A1	10-31-02	Beiersdorf AG		
/C.B./	AN	WO 02/098347 A2	12-12-2002	New York University		

Examiner Signature	/Courtney Brown/	Date Considered	11/27/2007
--------------------	------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Institute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/821,981
		Filing Date	April 12, 2004
		First Named Inventor	Seth ORLOW
		Group Art Unit	1615
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	ORLOW1A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/C.B./	AO	HU D-N et al., "Regulation of Melanogenesis by Human Unveal Melanocytes In Vitro", Chemical Abstracts, (June 23, 1997), Vol. 126, No. 25, abstract only.	
/C.B./	AP	Greenspan A.H. et al., "Acanthosis Nigricans-like Hyperpigmentation Secondary to Triazine Therapy", Archives of Dermatology, Feb. 1985), Vol. 121, No. 2, pp. 232-235, XP009037865.	
/C.B./	AQ	Knockaert M. et al., "Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors", Chemistry and Biology, (June 2000), Vol. 7, No. 6, pp. 411-422, XP001070114.	
/C.B./	AR	Márs U. et al., "New Thioureas and Related Substances Intended for Melonoma Targeting", Pigment Cell Research, (Aug. 1995), Vol. 8, No. 4, pp. 194-201, XP009037885.	
/C.B./	AS	Silen J.L. et al., "Screening for Novel Antimicrobials from Encoded Combinatorial Libraries by Using a Two-Dimensional Agar Format", Antimicrobial Agents and Chemotherapy, (June 1998), Vol.42, No. 6, pp. 1447-1753, XP002203675.	

Examiner Signature	/Courtney Brown/	Date Considered	11/27/2007
-----------------------	------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/821,981
Filing Date	April 12, 2004
First Named Inventor	Seth ORLOW et al.
Group Art Unit	1615
Examiner Name	-
Attorney Docket Number	ORLOW1A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/C.B./	AA	CHIU, EASTER, et al., Postnatal Ocular Expression of Tyrosinase and Related Proteins: Disruption by the Pink-eyed Unstable (p ^u) Mutation, March 19, 1993, pp. 301-305, Vol. 57	
/C.B./	AB	DURHAM-PIERRE, D., et al., African Origin of an intragenic deletion of the Human P Gene in Tyrosinase Positive Oculocutaneous Albinism, NATURE GENETICS 7, June 1994, pp. 176-179	
/C.B./	AC	GAHL, WILLIAM A., et al., Melanosomal Tyrosine Transport in Normal and Pink-eyed Dilution Murine Melanocytes, PIGMENT CELL RESEARCH, June 9, 1995, pp. 229-233, Vol. 8	
/C.B./	AD	GARDNER, JOHN M., et al., The Mouse Pink-Eyed Dilution Gene: Association with Human Prader-Willi and Angelman Syndromes, SCIENCE 257, August 21, 1992, pp. 1121-1124	
/C.B./	AE	HEARING, VINCENT J., Invited Editorial: Unraveling the Melanocyte, AM. J. HUM. GENET. 52, 1993, pp. 1-7	
/C.B./	AF	IIDA, KOICHI, et al., Potent Inhibitors of Tyrosinase Activity and Melanin Biosynthesis from Rheum Officinale, Planta Med. 61, March 12, 1995, pp. 425-428, GEORGE THIEME STUTTGART, NEW YORK	
/C.B./	AG	KORNER, ANN, et al., Mammalian Tyrosinase Catalyzes Three Reactions in the Biosynthesis of Melanin, SCIENCE, September 17, 1982, pp. 1163-1165, Vol. 217	
/C.B./	AH	LAMOREUX, LYNN M., et al., The Pinkeyed-Dilution Protein and The Eumelanin/Pheomelanin Switch: In Support of a Unifying Hypothesis, PIGMENT CELL RESEARCH 8, September 4, 1995, pp. 263-270	
/C.B./	AI	LERNER, AARON BUNSEN, et al., Physiology Rev. 30, Biochemistry of Melanin Formation, January 1950, pp. 91-126, Vol. 30	
/C.B./	AJ	ORLOW, SETH J., et al., The Pink-Eyed Dilution Locus Controls the Biogenesis of Melanosomes and Levels of Melanosomal Proteins in the Eye, EXP. EYE RES., 1999, pp. 147-154, Vol. 68, Academic Press	
/C.B./	AK	ORLOW, SETH J., The Pigmentary System: Physiology and Pathophysiology 97, The Biogenesis of Melanosomes, pp. 97-106, Chapter 6, Oxford University Press, New York, Nordlund, et al., eds.	
/C.B./	AL	REISH, ORIT, et al., Tyrosine Inhibition Due to Interaction of Homocyst(e)ine with Copper: The Mechanism for Reversible Hypopigmentation in Homocystinuria Due to Cystathionine β -Synthase Deficiency, AM. J. HUM. GENET., April 11, 1995, pp. 127-132, Vol. 57	

Examiner
Signature


/Courtney Brown/

Date
Considered

11/27/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/821,981
Filing Date	April 12, 2004
First Named Inventor	Seth ORLOW et al.
Group Art Unit	1615
Examiner Name	-
Attorney Docket Number	ORLOW1A

Sheet	2	of	2
-------	---	----	---

[illegible]

/Courtney Brown/

11/27/2007

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.